On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend including the peptide BPC-157 on the Section 503A Bulks List, which would allow regulated compounding pharmacies to legally produce it. This recommendation, while non-binding, marks a significant step toward safer, regulated access to BPC-157 for patients, replacing unregulated sources. The Precision Peptide Company, which produces BPC-157 patches, sees this as progress toward quality, transparency, and patient safety in peptide therapies. The FDA's final decision is pending, and the company continues to advance its pharmaceutical-grade peptide products and commercialization efforts.
Strategy claims its current capital structure can sustain interest payments and preferred stock dividends even if Bitcoin falls 11.4% annually for 5.8 years. The company holds 843,775 BTC and $3.225 billion in cash reserves to support obligations tot...
Michael Saylor, CEO of Strategy, released a 953-hour reading curriculum covering history, economics, war, technology, and Bitcoin to train future leaders on understanding Bitcoin deeply. His program includes classics like The Story of Civilization an...
Hyperliquid has used $1.2 million of its revenue to burn 20.64K HYPE tokens as part of its deflationary strategy to control supply and support the token price, which remains below $60. Since August 2025, the project has generated $800 million in net ...
The Federal Reserve and Bank of Japan will announce interest rate decisions next week, expected to hold rates steady. The Fed's rate has been stable since December 2025, with a 38% chance of a hike due to rising oil prices, but a hold remains most li...
XRP is at a critical juncture with the $1.08 support level under pressure. Holding above this level could lead to a bullish move toward $1.20 and possibly higher resistance near $1.30, signaling a potential recovery. However, if XRP falls below $1.08...
